Neumora Reports $182.5M Cash in 2025, Advances Alzheimer's Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy NMRA?
"We saw significant progress in 2025, laying the foundation for a catalyst-rich year ahead as we advance our pipeline of next-generation therapies for people living with brain diseases," said Paul Berns, co-founder, chairman and CEO of Neumora. "In the first quarter of 2026, we confirmed next steps for navacaprant and our M4 franchise, as well as generated compelling results supporting the potential unsurpassed profile of NMRA-511 in Alzheimer's disease agitation, which we built upon today with the announcement of additional data from a pre-specified analysis." As of December 31, 2025, Neumora had cash and cash equivalents of $182.5M. The company expects that its cash, cash equivalents and marketable securities as of December 31, 2025, will enable it to fund its operating plan into the third quarter of 2027.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NMRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NMRA
Wall Street analysts forecast NMRA stock price to rise
8 Analyst Rating
5 Buy
2 Hold
1 Sell
Moderate Buy
Current: 2.470
Low
3.00
Averages
9.33
High
18.00
Current: 2.470
Low
3.00
Averages
9.33
High
18.00
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neumora Therapeutics to Participate in Healthcare Conference
- Conference Participation: Neumora Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, showcasing its latest advancements in biopharmaceuticals, which is expected to attract attention from investors and industry experts, thereby enhancing the company's visibility in the capital markets.
- Live Webcast: The event will feature a live webcast available on the company's website, allowing global investors to stay updated on Neumora's developments in real-time, enhancing transparency and facilitating interaction with potential investors, which could positively impact future fundraising activities.
- Therapeutic Pipeline Overview: Neumora's pipeline focuses on addressing underserved diseases, demonstrating its innovative approach in neuroscience drug development aimed at improving treatment outcomes and quality of life for patients, further solidifying its competitive position in the biopharmaceutical industry.
- Company Mission: Neumora's mission is to redefine neuroscience drug development by introducing next-generation therapies to tackle contemporary medical challenges, emphasizing its strategic importance in driving medical innovation and improving patient lives.
See More
Schall Law Firm Investigates Neumora Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, Inc. to determine if the company issued false or misleading statements that could affect investor rights.
- Legal Compliance Issues: The investigation focuses on whether Neumora failed to disclose information pertinent to investors, potentially leading to shareholder losses and impacting the company's reputation and future financing capabilities.
- Investor Rights Protection: Schall encourages affected shareholders to participate in the investigation and offers free legal consultations, aiming to help investors understand their rights and seek compensation.
- Securities Litigation Expertise: The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors worldwide, which underscores its professional capability and influence in protecting investor rights.
See More
Neumora Therapeutics Reports Positive Phase Ib Results for Alzheimer's Treatment
- Strong Financial Position: As of December 31, 2025, Neumora Therapeutics reported $182.5 million in cash and equivalents, expected to support operations into Q3 2027, demonstrating the company's financial resilience for ongoing R&D and market expansion.
- Clinical Trial Progress: The Phase Ib study of NMRA-511 showed clinically meaningful effects in Alzheimer's disease agitation with a favorable safety profile, potentially offering new hope for treatment options and enhancing the company's competitive edge in neuroscience.
- New Drug Development Updates: Neumora has fully enrolled participants for the KOASTAL-2 and KOASTAL-3 studies, with data expected in Q2 2026, which will provide critical support for the filing of navacaprant in major depressive disorder, further advancing its therapeutic applications.
- Challenges and Risks: Despite NMRA-215 showing leading weight loss data in a 12-week obesity study, unexpected adverse findings in a 13-week toxicology study have delayed clinical trials until Q1 2027, highlighting the challenges and uncertainties faced in drug development.
See More
Neumora Therapeutics Reports Q4 Earnings Miss and Financial Guidance
- Earnings Report Miss: Neumora Therapeutics reported a Q4 GAAP EPS of -$0.35, missing expectations by $0.02, indicating challenges in profitability that could affect investor confidence.
- Cash Reserves Status: As of December 31, 2025, Neumora had cash and cash equivalents of $182.5 million, ensuring operational funding for the next two years, providing short-term financial stability despite profitability issues.
- Financial Guidance Outlook: The company expects its cash, cash equivalents, and marketable securities as of December 31, 2025, to fund its operating plan into Q3 2027, demonstrating a degree of foresight in financial management.
- Clinical Trial Progress: Neumora has achieved positive results in early-stage trials for NMRA-511 related to Alzheimer's disease, suggesting that despite poor financial performance, advancements in product development may drive future growth.
See More
Schall Law Firm Investigates Neumora Therapeutics for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, focusing on potential violations of securities laws, which may involve false or misleading statements that could undermine investor confidence.
- Investor Rights: The investigation aims to protect shareholder rights and encourages affected investors to participate, indicating that the company faces legal risks that could negatively impact its stock price.
- Legal Expertise Support: Schall Law Firm specializes in securities class action lawsuits and offers free consultations, demonstrating its commitment and expertise in safeguarding investor rights.
- Potential Consequences: Should the investigation confirm violations by Neumora, the company may face significant legal liabilities, further affecting its market performance and investor trust.
See More
NMRA-511 Shows Promising Results in Alzheimer's Agitation
- Clinical Trial Results: NMRA-511 demonstrated a favorable safety profile in a Phase 1b study for Alzheimer's patients, with no somnolence or sedation, and significant improvements in agitation reflected by placebo-adjusted CMAI total score changes of -2.6 and -2.1 at Weeks 6 and 8, indicating its effectiveness in alleviating anxiety.
- Market Potential Forecast: William Blair projects peak U.S. sales of $1.8 billion for NMRA-511, viewing the early data as promising despite previous setbacks with the V1a receptor antagonist approach, suggesting a strong market outlook.
- Obesity Treatment Progress: Analyst Minter notes that positive Phase 2 data for NMRA-215 by year-end 2026 could represent a major inflection point for Neumora, with William Blair adding value to its model and modeling a 15% probability of success to unlock a greater than $2 billion market opportunity.
- Depression Asset Update: The KOASTAL-2/3 trials for monotherapy navacaprant in major depressive disorder are expected to read out in the second quarter of 2026, and while there is caution regarding its de-risking value, the update in the KOR antagonist space has intrigued investors.
See More
Neumora Therapeutics to Participate in Healthcare Conference
- Conference Participation: Neumora Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, showcasing its latest advancements in biopharmaceuticals, which is expected to attract attention from investors and industry experts, thereby enhancing the company's visibility in the capital markets.
- Live Webcast: The event will feature a live webcast available on the company's website, allowing global investors to stay updated on Neumora's developments in real-time, enhancing transparency and facilitating interaction with potential investors, which could positively impact future fundraising activities.
- Therapeutic Pipeline Overview: Neumora's pipeline focuses on addressing underserved diseases, demonstrating its innovative approach in neuroscience drug development aimed at improving treatment outcomes and quality of life for patients, further solidifying its competitive position in the biopharmaceutical industry.
- Company Mission: Neumora's mission is to redefine neuroscience drug development by introducing next-generation therapies to tackle contemporary medical challenges, emphasizing its strategic importance in driving medical innovation and improving patient lives.
See More
Schall Law Firm Investigates Neumora Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, Inc. to determine if the company issued false or misleading statements that could affect investor rights.
- Legal Compliance Issues: The investigation focuses on whether Neumora failed to disclose information pertinent to investors, potentially leading to shareholder losses and impacting the company's reputation and future financing capabilities.
- Investor Rights Protection: Schall encourages affected shareholders to participate in the investigation and offers free legal consultations, aiming to help investors understand their rights and seek compensation.
- Securities Litigation Expertise: The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors worldwide, which underscores its professional capability and influence in protecting investor rights.
See More
Neumora Therapeutics Reports Positive Phase Ib Results for Alzheimer's Treatment
- Strong Financial Position: As of December 31, 2025, Neumora Therapeutics reported $182.5 million in cash and equivalents, expected to support operations into Q3 2027, demonstrating the company's financial resilience for ongoing R&D and market expansion.
- Clinical Trial Progress: The Phase Ib study of NMRA-511 showed clinically meaningful effects in Alzheimer's disease agitation with a favorable safety profile, potentially offering new hope for treatment options and enhancing the company's competitive edge in neuroscience.
- New Drug Development Updates: Neumora has fully enrolled participants for the KOASTAL-2 and KOASTAL-3 studies, with data expected in Q2 2026, which will provide critical support for the filing of navacaprant in major depressive disorder, further advancing its therapeutic applications.
- Challenges and Risks: Despite NMRA-215 showing leading weight loss data in a 12-week obesity study, unexpected adverse findings in a 13-week toxicology study have delayed clinical trials until Q1 2027, highlighting the challenges and uncertainties faced in drug development.
See More
Neumora Therapeutics Reports Q4 Earnings Miss and Financial Guidance
- Earnings Report Miss: Neumora Therapeutics reported a Q4 GAAP EPS of -$0.35, missing expectations by $0.02, indicating challenges in profitability that could affect investor confidence.
- Cash Reserves Status: As of December 31, 2025, Neumora had cash and cash equivalents of $182.5 million, ensuring operational funding for the next two years, providing short-term financial stability despite profitability issues.
- Financial Guidance Outlook: The company expects its cash, cash equivalents, and marketable securities as of December 31, 2025, to fund its operating plan into Q3 2027, demonstrating a degree of foresight in financial management.
- Clinical Trial Progress: Neumora has achieved positive results in early-stage trials for NMRA-511 related to Alzheimer's disease, suggesting that despite poor financial performance, advancements in product development may drive future growth.
See More
Schall Law Firm Investigates Neumora Therapeutics for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Neumora Therapeutics, focusing on potential violations of securities laws, which may involve false or misleading statements that could undermine investor confidence.
- Investor Rights: The investigation aims to protect shareholder rights and encourages affected investors to participate, indicating that the company faces legal risks that could negatively impact its stock price.
- Legal Expertise Support: Schall Law Firm specializes in securities class action lawsuits and offers free consultations, demonstrating its commitment and expertise in safeguarding investor rights.
- Potential Consequences: Should the investigation confirm violations by Neumora, the company may face significant legal liabilities, further affecting its market performance and investor trust.
See More
NMRA-511 Shows Promising Results in Alzheimer's Agitation
- Clinical Trial Results: NMRA-511 demonstrated a favorable safety profile in a Phase 1b study for Alzheimer's patients, with no somnolence or sedation, and significant improvements in agitation reflected by placebo-adjusted CMAI total score changes of -2.6 and -2.1 at Weeks 6 and 8, indicating its effectiveness in alleviating anxiety.
- Market Potential Forecast: William Blair projects peak U.S. sales of $1.8 billion for NMRA-511, viewing the early data as promising despite previous setbacks with the V1a receptor antagonist approach, suggesting a strong market outlook.
- Obesity Treatment Progress: Analyst Minter notes that positive Phase 2 data for NMRA-215 by year-end 2026 could represent a major inflection point for Neumora, with William Blair adding value to its model and modeling a 15% probability of success to unlock a greater than $2 billion market opportunity.
- Depression Asset Update: The KOASTAL-2/3 trials for monotherapy navacaprant in major depressive disorder are expected to read out in the second quarter of 2026, and while there is caution regarding its de-risking value, the update in the KOR antagonist space has intrigued investors.
See More
